Publications by authors named "Margaux Crabtree"
Objectives: Fatigue is commonly reported in patients with Crohn's disease (CD) and ulcerative colitis (UC), including patients with inactive disease. We explored the impact of fatigue on healthcare utilization (HCU) and work productivity and activity impairment (WPAI).
Methods: Data collected between 2017 and 2022 were analyzed from the CorEvitas IBD Registry.
Article Synopsis
- Early detection and effective management of psoriatic arthritis (PsA) in psoriasis patients are crucial yet often overlooked medical needs.
- The study compared patients with psoriasis who screened positive for PsA using the Psoriasis Epidemiology Screening Tool (PEST) to those with confirmed PsA and those who screened negative, analyzing demographics, disease impact, and symptom states.
- Results showed that screen-positive and PsA patients had similar disease profiles, with a significant proportion reaching an acceptable symptom state, highlighting the importance of screening for PsA in psoriasis patients.
Article Synopsis
- The study aims to develop new treatment guidelines for rheumatoid arthritis (RA) by analyzing current treatment practices using observational data from the CorEvitas RA registry.
- Data was collected from 6015 patients starting their first biologic or targeted synthetic therapy, showing a shift from tumor necrosis factor inhibitors to Janus kinase inhibitors over the years.
- Findings highlight a high variety of treatment patterns and the common occurrence of therapy cycling, indicating a need for tailored guidelines while noting the statistical complexities in comparing different treatment sequences.
Article Synopsis
- Fecal urgency, a symptom of Ulcerative Colitis (UC), was studied to understand its association with patient characteristics and treatment changes among 400 patients in the CorEvitas Inflammatory Bowel Disease Registry.
- The study classified patients into four groups based on their urgency status at enrollment and after 6 months, finding that those with persistent or changing urgency reported more comorbidities and had worse overall health outcomes.
- Results indicated that patients experiencing urgency were more likely to change treatments within the 6-month follow-up, suggesting urgency may indicate inadequate therapy and negatively impacts quality of life.
Article Synopsis
- The study analyzed treatment patterns in rheumatoid arthritis (RA) patients initiating their first biologic or targeted synthetic therapy from 2012 to 2021 using data from the CorEvitas RA registry.
- Initially, 80% of patients received tumor necrosis factor inhibitors (TNFi) as their first treatment, but usage shifted to Janus kinase inhibitors (JAKi) post-2015, and therapy cycling was common among patients who changed treatments multiple times.
- The findings indicate significant variability in RA treatment after the first-line therapy, paving the way for developing new treatment guidelines while also highlighting challenges in comparing outcomes due to diverse treatment sequences.
Background: To evaluate disease burden and patient-reported outcomes (PROs) of ulcerative colitis (UC) patients at enrollment into CorEvitas' Inflammatory Bowel Disease Registry by therapy class.
Methods: Between May 3, 2017 and September 3, 2019, 773 UC registry patients were categorized by therapy class at enrollment: patients on 5-aminosalicylic acids (5-ASAs) only ( = 290), and patients on biologics/Janus kinase inhibitors (JAKi) alone or in combination with 5-ASAs or immunosuppressant therapies (BIO/JAKi) ( = 315). To quantify between group differences, the mean/proportional differences and corresponding 95% CIs were calculated.
Introduction: The aim of this work is to describe real-world biologic-experienced psoriasis patients initiating ixekizumab by prior biologic therapy status and compare the effectiveness of ixekizumab between patients who previously failed secukinumab and those who failed other biologics. We hypothesized that (1) clinical outcomes and patient-reported outcomes would improve following a switch to IXE, and (2) there would be no differences in responses between patients who previously failed secukinumab and those who failed other biologics.
Methods: Participants (n = 419) included adult psoriasis patients enrolled in the CorEvitas Psoriasis Registry through 9/10/20 who switched to ixekizumab after discontinuing another biologic.
Background: There are limited real-world data characterizing perianal fistulae in patients with Crohn's disease (CD).
Aim: To describe characteristics of patients with CD with and without perianal fistulae.
Methods: In this cross-sectional study, characteristics, treatment history, and health outcomes of patients with CD enrolled in the CorEvitas IBD Registry were described according to perianal fistula status (current/previous or none).
Objectives: There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes.
Methods: Adult patients with psoriasis who initiated ixekizumab and completed a 6-month follow-up visit were enrolled from the Corrona Psoriasis Registry.
Background: Real-world studies evaluating patients with challenging-to-treat localizations of psoriasis (scalp, nail, and palmoplantar) are limited.
Objective: To characterize patients with versus without psoriasis in challenging-to-treat areas seen in routine US clinical practice.
Methods: This retrospective observational study included all adult patients with psoriasis enrolled in the Corrona Psoriasis Registry between April 2015 and May 2018 who initiated a biologic therapy at registry enrollment.
Article Synopsis
- The study assessed how comorbidity burden and obesity impact the effectiveness of tocilizumab (TCZ) in treating rheumatoid arthritis patients.
- Patients were categorized based on comorbidity and obesity, and the study compared their disease activity improvement after 6 and 12 months of treatment.
- Results showed that TCZ was effective for all patient groups, with no significant differences in treatment outcomes between those with high versus low comorbidity or obesity status.
Importance: Somatic mutations in BAP1 (BRCA1-associated protein 1 gene) are frequently identified in uveal melanoma. To date, the role of germline BAP1 mutations in uveal melanoma has not been characterized.
Objective: To characterize the clinical phenotype of uveal melanoma in patients with germline BAP1 mutations.